Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Major Pharmaceuticals

US Class II Ongoing · initiated 2026-07-13

Subpotent Drug

Major Pharmaceuticals

US Class II Ongoing · initiated 2026-07-13

Subpotent Drug

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2026-07-13

Presence of Precipitate: medication was crystallizing and particles floating in the bottle

Major Pharmaceuticals

US Class II Ongoing · initiated 2026-07-13

Subpotent Drug

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-07-09

Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator

Ascend Laboratories, LLC

US Class II Ongoing · initiated 2026-07-08

Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

JAMP Chlorthalidone 12.5 mg Tablets

Canada Type III Ongoing · initiated 2026-07-06

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

Chiesi USA, Inc.

US Class II Ongoing · initiated 2026-07-06

Lack of Assurance of Sterility

Fludeoxyglucose (18F) Injection

Canada Type III Ongoing · initiated 2026-07-02

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

MYLAN PHARMACEUTICALS INC

US Class II Ongoing · initiated 2026-07-02

Presence of precipitate

Victory Medical Center Pharmacy

US Class I Ongoing · initiated 2026-07-01

Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.

Ascend Laboratories, LLC

US Class III Ongoing · initiated 2026-06-30

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and T…

Ascend Laboratories, LLC

US Class III Ongoing · initiated 2026-06-30

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and T…

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-06-29

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-06-29

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Cipla USA, Inc.

US Class II Ongoing · initiated 2026-06-29

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Lannett Company Inc.

US Class II Ongoing · initiated 2026-06-26

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Remifentanil hydrochloride for injection 1 mg/vial

Canada Type II Ongoing · initiated 2026-06-26

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Spiriva 18mcg capsule

Canada Type III Ongoing · initiated 2026-06-25

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Bell Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-06-25

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).